Is it possible to predict the onset of nocturnal asymptomatic hypoglycemia in patients with type 1 diabetes receiving insulin degludec? Potential role of previous day and next morning glucose values

被引:1
作者
Takahashi, Hiroshi [1 ]
Nishimura, Rimei [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol, Tokyo, Japan
关键词
Continuous glucose monitoring; Nocturnal asymptomatic hypoglycemia; Type; 1; diabetes; GLYCEMIC VARIABILITY; JAPANESE PATIENTS; CROSS-OVER; GLARGINE; ADOLESCENTS; MORTALITY; FREQUENCY; DURATION; ANALOG;
D O I
10.1111/jdi.13363
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction To determine whether the occurrence of nocturnal asymptomatic, serious, clinically important hypoglycemia (NSH) could be predicted based on glucose values on the previous day and the following morning of the day of onset. Materials and Methods This study examined patients with type 1 diabetes who underwent continuous glucose monitoring assessments and received insulin degludec. NSH was defined as glucose level <54 mg/dL detected between 24.00 and 06.00 hours. The participants were evaluated to determine the following: (i) glucose level at bedtime (24.00 hours) on the previous day (BG); (ii) fasting glucose level (FG); and (iii) the range of post-breakfast glucose elevation. The patients were divided into those with NSH and those without, and compared usingt-tests. Optimal cut-off values for relevant parameters for predicting NSH were determined using receiver operating characteristic analysis. Results The study included a total of 31 patients with type 1 diabetes (mean glycated hemoglobin value 7.8 +/- 0.7%). NSH occurred in eight patients (26%). BG and FG were significantly lower in those with NSH than in those without (P = 0.044,P < 0.001). The range of post-breakfast glucose elevation was significantly greater in those with NSH than in those without. The cut-off glucose values for predicting NSH were as follows: BG = 90 mg/dL (sensitivity 0.83/specificity 0.75/area under the curve 0.79,P = 0.017) and FG = 69 mg/dL (0.83/0.75/0.86,P = 0.003). Conclusions The results showed that in patients with type 1 diabetes receiving insulin degludec, BG <90 mg/dL and FG <69 mg/dL had an approximately 80% probability of predicting the occurrence of NSH.
引用
收藏
页码:365 / 373
页数:9
相关论文
共 28 条
[1]   Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes [J].
Amiel, Stephanie A. ;
Aschner, Pablo ;
Childs, Belinda ;
Cryer, Philip E. ;
de Galan, Bastiaan E. ;
Heller, Simon R. ;
Frier, Brian M. ;
Gonder-Frederick, Linda ;
Jones, Timothy ;
Khunti, Kamlesh ;
Leiter, Lawrence A. ;
McCrimmon, Rory J. ;
Luo, Yingying ;
Seaquist, Elizabeth R. ;
Vigersky, Robert ;
Zoungas, Sophia .
DIABETOLOGIA, 2017, 60 (01) :3-6
[2]   Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects [J].
Becker, RHA ;
Frick, AD ;
Burger, F ;
Potgieter, JH ;
Scholtz, H .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (08) :435-443
[3]   Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine [J].
Birkeland, Kare I. ;
Home, Philip D. ;
Wendisch, Ulrich ;
Ratner, Robert E. ;
Johansen, Thue ;
Endahl, Lars A. ;
Lyby, Karsten ;
Jendle, Johan H. ;
Roberts, Anthony P. ;
DeVries, J. Hans ;
Meneghini, Luigi F. .
DIABETES CARE, 2011, 34 (03) :661-665
[4]   Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact? [J].
Choudhary, P. ;
Davies, C. ;
Emery, C. J. ;
Heller, S. R. .
DIABETIC MEDICINE, 2013, 30 (08) :914-917
[5]   RESTORATION OF HYPOGLYCEMIA AWARENESS IN PATIENTS WITH LONG-DURATION INSULIN-DEPENDENT DIABETES [J].
CRANSTON, I ;
LOMAS, J ;
MARAN, A ;
MACDONALD, I ;
AMIEL, SA .
LANCET, 1994, 344 (8918) :283-287
[6]  
DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z
[7]   Are bedtime nutritional strategies effective in preventing nocturnal hypoglycaemia in patients with type 1 diabetes? [J].
Desjardins, K. ;
Brazeau, A. -S. ;
Strychar, I. ;
Rabasa-Lhoret, R. .
DIABETES OBESITY & METABOLISM, 2014, 16 (07) :577-587
[8]   Insulin degludec: overview of a novel ultra long-acting basal insulin [J].
Gough, S. C. L. ;
Harris, S. ;
Woo, V. ;
Davies, M. .
DIABETES OBESITY & METABOLISM, 2013, 15 (04) :301-309
[9]   Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes [J].
Heise, T. ;
Hermanski, L. ;
Nosek, L. ;
Feldman, A. ;
Rasmussen, S. ;
Haahr, H. .
DIABETES OBESITY & METABOLISM, 2012, 14 (09) :859-864
[10]   Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial [J].
Heller, Simon ;
Buse, John ;
Fisher, Miles ;
Garg, Satish ;
Marre, Michel ;
Merker, Ludwig ;
Renard, Eric ;
Russell-Jones, David ;
Philotheou, Areti ;
Francisco, Ann Marie Ocampo ;
Pei, Huiling ;
Bode, Bruce .
LANCET, 2012, 379 (9825) :1489-1497